PB-EPHB4-CAR T-cell therapy (MaxCyte)

N/A

Report date: 2025/01/26 16:40:16

Base Information

Drug NamePB-EPHB4-CAR T-cell therapy (MaxCyte)
Drug Alias NameAnti-EPHB4 CAR T-cell therapy (MaxCyte)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionEphrin type-B receptor 4 modulators
TargetsEphrin type-B receptor 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMaxcyte Inc
China Registration ClassN/A

Develop Information

Active CompaniesMaxcyte Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A